The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer
Abstract
Purpose: Previous research evaluating adherence to tamoxifen therapy among women with early-stage breast cancer has revealed adherence estimates ranging from 25% to 96%. No previous studies have focused on adherence to adjuvant aromatase inhibitors. Methods: We used longitudinal claims data from three large commercial health programs to estimate adherence with anastrozole therapy among women with early-stage breast cancer. Adherence was defined as the proportion of days that patients had medication available over the observation period (ie, days covered); women with fewer than 80% of days covered were defined as nonadherent. Results: More than 12,000 women in the databases were found to have new anastrozole prescription claims during the period of study: 1,498 women were classified as having early-stage disease in one commercial health program (Plan A) data set, 1,899 women in another program (Plan B) data set, and 8,994 women in MarketScan, a commercial data set made up of several health programs. Mean adherence over the first 12 months of therapy ranged from 82% to 88% in the three data sets. Between 19% and 28% of women had fewer than 80% of days covered. For women with 36 months of continuous eligibility, the mean adherence decreased each year, ranging from 78% to 86% in year 1 to 62% to 79% in year 3 within the three data sets. Conclusion: A substantial proportion of women with early-stage breast cancer may be suboptimally adherent to adjuvant anastrozole therapy. Future research should focus on the identification of patients at risk for nonadherence with oral hormonal therapy for breast cancer and the development of interventions to improve adherence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Adherence to Long-Term Therapies: Evidence for Action
De Geest, S., & Sabaté, E. (2003) · European Journal of Cardiovascular Nursing · doi:10.1016/s1474-5151(03)00091-4 · Cited by 6,272
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Fisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., Dimitrov, N. V., Wolmark, N., Wickerham, D. L., Fisher, E. R., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200802 · Cited by 1,464
Coates, A. S., Keshaviah, A., Thürlimann, B., Mouridsen, H., Mauriac, L., Forbes, J. F., Paridaens, R., Castiglione-Gertsch, M., Gelber, R. D., Colleoni, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8617 · Cited by 910
Dose-Response Effect of Adjuvant Chemotherapy in Breast Cancer
Bonadonna, G., & Valagussa, P. (1981) · New England Journal of Medicine · doi:10.1056/nejm198101013040103 · Cited by 774
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.071 · Cited by 676
Self-citationCompliance with therapeutic regimens
Jay, S., Litt, I. F., & Durant, R. H. (1984) · Journal of Adolescent Health Care · doi:10.1016/s0197-0070(84)80012-1 · Cited by 666
Persistence of Use of Lipid-Lowering Medications: A Cross-National Study
Avorn, J., Monette, J., Lacour, A., Bohn, R. L., Monane, M., Mogun, H., & LeLorier, J. (1998) · JAMA · doi:10.1001/jama.279.18.1458 · Cited by 634
Adherence to Therapy With Oral Antineoplastic Agents
Partridge, A. H. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.9.652 · Cited by 584
Self-citationChoo, P. W., Rand, C. S., Inui, T. S., Lee, M.-L. T., Cain, E., Cordeiro-Breault, M., Canning, C., & Platt, R. (1999) · Medical Care · doi:10.1097/00005650-199909000-00002 · Cited by 546
Steiner, J. F., Koepsell, T. D., Fihn, S. D., & Inui, T. S. (1988) · Medical Care · doi:10.1097/00005650-198808000-00007 · Cited by 458
Overview of patient compliance with medication dosing: a literature review.
Greenberg, R. N. (1984) · PubMed · Cited by 419
Adherence to tamoxifen over the five-year course
Lash, T. L., Fox, M. P., Westrup, J. L., Fink, A. K., & Silliman, R. A. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9193-0 · Cited by 320
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2004) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000115858.45890.53 · Cited by 315
Waterhouse, D. M., Calzone, K. A., Mele, C., & Brenner, D. E. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.6.1189 · Cited by 313
Intentional and non-intentional non-adherence to medication amongst breast cancer patients
Atkins, L., & Fallowfield, L. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.03.004 · Cited by 300
Adjuvant Tamoxifen: Predictors of Use, Side Effects, and Discontinuation in Older Women
Demissie, S., Silliman, R. A., & Lash, T. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.322 · Cited by 300
Fink, A. K., Gurwitz, J., Rakowski, W., Guadagnoli, E., & Silliman, R. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.064 · Cited by 281
Early discontinuation of tamoxifen: A Lesson for oncologists
Barron, T. I., Connolly, R., Bennett, K., Feely, J., & Kennedy, M. J. (2007) · Cancer · doi:10.1002/cncr.22485 · Cited by 279
Noncompliance With Congestive Heart Failure Therapy in the Elderly
Monane, M. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.154.4.433 · Cited by 277
Treatment for glaucoma: adherence by the elderly.
Gurwitz, J. H., Glynn, R. J., Monane, M., Everitt, D. E., Gilden, D., Smith, N., & Avorn, J. (1993) · American Journal of Public Health · doi:10.2105/ajph.83.5.711 · Cited by 266
Swedish Breast Cancer Cooperative Group (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.21.1543 · Cited by 261
Monane, M., Bohn, R. L., Gurwitz, J. H., Glynn, R. J., Levin, R., & Avorn, J. (1996) · American Journal of Public Health · doi:10.2105/ajph.86.12.1805 · Cited by 253
Adherence beliefs among breast cancer patients taking tamoxifen
Grunfeld, E. A., Hunter, M. S., Sikka, P., & Mittal, S. (2005) · Patient Education and Counseling · doi:10.1016/j.pec.2004.10.005 · Cited by 245
Treatment compliance in childhood and adolescence
Tebbi, C. K. (1993) · Cancer · doi:10.1002/1097-0142(19930515)71:10+<3441::aid-cncr2820711751>3.0.co;2-p · Cited by 187
Blackwell, B. (1972) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1972135part2841 · Cited by 179
DAVIES, C. (2004) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(04)00121-5 · Cited by 170
Prospects for Antiestrogen Chemoprevention of Breast Cancer
Love, R. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.18 · Cited by 54
The behavioral dynamics of clinical trials
Leventhal, H., Nerenz, D. R., Leventhal, E. A., Love, R. R., & Bendena, L. M. (1991) · Preventive Medicine · doi:10.1016/0091-7435(91)90014-u · Cited by 54
Compliance and clinical trials
Urquhart, J. (1991) · The Lancet · doi:10.1016/0140-6736(91)92896-a · Cited by 22
Skeletal scintigraphy in patients with bilateral retinoblastoma
Pratt, C. B., Crom, D. B., Chenaille, P. J., Magill, L., & Meyer, D. (1990) · Cancer · doi:10.1002/1097-0142(19900101)65:1<17::aid-cncr2820650106>3.0.co;2-i · Cited by 13
Cited by
Hershman, D. L., Shao, T., Kushi, L. H., Buono, D., Tsai, W. Y., Fehrenbacher, L., Kwan, M., Gomez, S. L., & Neugut, A. I. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1132-4 · Cited by 870
Hershman, D. L., Kushi, L. H., Shao, T., Buono, D., Kershenbaum, A., Tsai, W.-Y., Fehrenbacher, L., Lin Gomez, S., Miles, S., & Neugut, A. I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9655 · Cited by 828
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., Giordano, S. H., Hudis, C. A., Malin, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3756 · Cited by 796
Self-citationMurphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2114-5 · Cited by 708
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Goss, P. E., Ingle, J. N., Pritchard, K. I., Robert, N. J., Muss, H., Gralow, J., Gelmon, K., Whelan, T., Strasser-Weippl, K., Rubin, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604700 · Cited by 644
Self-citation
Metadata
- Authors
- Partridge, A. H., LaFountain, A., Mayer, E., Taylor, B. S., Winer, E., & Asnis-Alibozek, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-02-01
- Volume
- 26
- Issue
- 4
- Pages
- 556-562
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2154734961
- Cited by
- 482
- References
- 36
- FWCI
- 26.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.